DMAC DiaMedica Therapeutics Inc

Price (delayed)

$7.56

Market cap

$407.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.72

Enterprise value

$402.73M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 4

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. ...

Highlights
DMAC's debt is down by 37% year-on-year and by 13% since the previous quarter
DiaMedica Therapeutics's equity has increased by 41% YoY but it has decreased by 19% from the previous quarter
The net income has contracted by 27% YoY and by 7% from the previous quarter
The quick ratio has contracted by 26% from the previous quarter and by 10% YoY

Key stats

What are the main financial stats of DMAC

DMAC stock price

How has the DiaMedica Therapeutics stock price performed over time
Intraday
-2.83%
1 week
14.03%
1 month
15.95%
1 year
10.2%
YTD
-5.03%
QTD
7.39%

Financial performance

How have DiaMedica Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.17M
Net income
-$37.59M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 27% YoY and by 7% from the previous quarter
The operating income has contracted by 23% YoY and by 7% from the previous quarter

Price vs fundamentals

How does DMAC's price correlate with its fundamentals

Growth

What is DiaMedica Therapeutics's growth rate over time

Valuation

What is DiaMedica Therapeutics stock price valuation
P/E
N/A
P/B
10.63
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 4.3% YoY
The stock's price to book (P/B) is 195% more than its 5-year quarterly average of 3.7 and 37% more than its last 4 quarters average of 8.0
DiaMedica Therapeutics's equity has increased by 41% YoY but it has decreased by 19% from the previous quarter

Efficiency

How efficient is DiaMedica Therapeutics business performance
DiaMedica Therapeutics's return on invested capital has decreased by 6% YoY

Dividends

What is DMAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DMAC.

Financial health

How did DiaMedica Therapeutics financials performed over time
DiaMedica Therapeutics's total liabilities has soared by 55% YoY and by 14% from the previous quarter
The total assets is up by 43% year-on-year but it is down by 15% since the previous quarter
DMAC's debt is 100% smaller than its equity
DiaMedica Therapeutics's debt to equity has plunged by 100% YoY
DiaMedica Therapeutics's equity has increased by 41% YoY but it has decreased by 19% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.